Abstract |
Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation ( RAEB- T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged </=60 years and 35% aged >60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high- or low-dose IL-2. Patients aged up to 55 years with an HLA-identical sibling donor were eligible for allogeneic bone marrow transplantation. The median relapse-free survival was 12.5 months, with a probability of ongoing CR at 6.5 years of 19%. Overall survival of all patients was 8 months, and 21 months for the CR patients. Median survival was significantly longer among patients aged </=60 years than among the older patients (16 vs 6 months, p<0.001). Median duration of survival and relapse-free survival were not statistically different in the two IL-2 treatment arms.
|
Authors | A Ganser, G Heil, G Seipelt, W Hofmann, J T Fischer, W Langer, W Brockhaus, K Kolbe, T H Ittel, N Brack, H G Fuhr, P Knuth, K Höffken, L Bergmann, D Hoelzer |
Journal | Annals of hematology
(Ann Hematol)
Vol. 79
Issue 1
Pg. 30-5
(Jan 2000)
ISSN: 0939-5555 [Print] Germany |
PMID | 10663618
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Interleukin-2
- Cytarabine
- Etoposide
- Idarubicin
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cytarabine
(administration & dosage)
- Dose-Response Relationship, Drug
- Etoposide
(administration & dosage)
- Female
- Humans
- Idarubicin
(administration & dosage)
- Immunotherapy
- Interleukin-2
(therapeutic use)
- Leukemia, Myeloid
(drug therapy)
- Male
- Middle Aged
- Myelodysplastic Syndromes
(drug therapy, therapy)
- Prospective Studies
- Survival Rate
|